Subscribe
shutterstock_555165064_kitreel
2 November 2022Big PharmaStaff Writer

Big pharma co buys $16.6bn for heart tech company

Johnson & Johnson (J&J) has agreed to acquire  Abiomed, a cardiovascular medical technology company, for $16.6 billion.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Novo Nordisk makes $1.1bn bid for biopharma company
2 September 2022   Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.
Americas
Pfizer bolsters haematology expertise with $5.4bn deal
9 August 2022   Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.
Americas
MSD makes $1.4bn bid on biopharma company
22 November 2022   Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Novo Nordisk makes $1.1bn bid for biopharma company
2 September 2022   Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.
Americas
Pfizer bolsters haematology expertise with $5.4bn deal
9 August 2022   Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.
Americas
MSD makes $1.4bn bid on biopharma company
22 November 2022   Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.

More on this story

Americas
Novo Nordisk makes $1.1bn bid for biopharma company
2 September 2022   Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.
Americas
Pfizer bolsters haematology expertise with $5.4bn deal
9 August 2022   Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.
Americas
MSD makes $1.4bn bid on biopharma company
22 November 2022   Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent